RESEARCHER PROFILE
Huiwen Pang, PhD candidate (Filmed Nov 2023)
Australian Institute for Bioengineering and Nanotechnology
University of Queensland
Australia
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
The treatment and prevention of Type 1 diabetes remain largely unknown due to the autoimmune system’s attack on the pancreas and beta cells. Huiwen’s research focuses on nano based drug formulations for Type 1 diabetes treatment due to unknown triggering mechanism of autoimmune system attacking pancreas.
Huiwen Pang’s goal to make his own mark in the field of biomedical health is driven by inspiration from distinguished scholars and their research outcomes. Huiwen is also driven by having meaningful impact on people’s health, inspired by the challenges faced by patients with diabetes, including his own grandfather.
Huiwen enjoys hiking each weekend in Brisbane and the surrounding areas, taking in the mountains and the lakes which give he finds relaxing.
-
Dr Paul Griffin
MATER HEALTH SERVICES, QUEENSLAND, AUSTRALIA
-
Neonatal respiratory trials in sick & preterm newborn infants
Prof Brett J. Manley leads and collaborates on large national and international randomised clinical trials in neonatology. He previously collaborated on 4 randomised trials of nasal high-flow as non-invasive respiratory support for preterm and term infants, all of which were published in N Engl J Med. Recently he led the PLUSS trial of intratracheal budesonide for extremely preterm infants, that recruited in 21 NICUs across 4 countries, the results of which were published in JAMA. PLUSS was awarded the Australian Clinical Trials Alliance Trial of the Year in 2025. Another passion of his is mentoring and supervising early career researchers to undertake their own clinical trials.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
